Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Immorna Biotherapeutics, Inc.
With
ICON plc
This is a phase 1 study looking to enroll a total of 72 patients.
For phase 1, two cohorts will be explored (18-64 age group and 65+ age group) for a total of 72 subjects. The subjects will be enrolled and randomized to either placebo or JCXH-221. A low dose of JCXH-221 will be explored vs placebo for each age group first.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Sex: Male or female; female subjects may be of childbearing potential, of nonchildbearing potential, or postmenopausal.
Age: 18 years of age or older, at screening.
Status: Healthy subjects.
Subjects must have completed the full doses for primary vaccination with an approved SARS-CoV-2 vaccine and may have received booster dose(s), with the last vaccination (can be 2nd dose of primary vaccination or booster dose) having occurred at least 4 months prior to enrollment.
You may not be if
Current or prior symptomatic or asymptomatic SARS-CoV-2 infection confirmed by an approved or authorized rapid antigen test on Day 1 or within 4 months prior to Day 1.
Subjects with significant exposure (as defined by current CDC guidance) to someone with laboratory confirmed SARS-CoV-2 infection or COVID-19 with the past 14 days prior to the Screening visit.
Subjects with fever or signs of acute infection at the time of enrollment and vaccination.
Subjects who are taking medications that may prevent or treat COVID-19.
Subjects who received convalescent serum or prior therapeutic antibodies against SARS-CoV-2 within 4 months before Day 1.
Subjects with history of myocarditis or pericarditis, or with AEs after mRNA vaccination that are in nature and severity beyond the common AEs expected and necessitating medical intervention.
Subjects with active or suspected immunosuppression, immunodeficiency, or autoimmune disease.
